Cheng‐Ming Sun

Qingdao University — China

Medicine · Health Sciences

24h-index10.4kcitations150works0.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Renal cell carcinoma treatment(75), Cancer Immunotherapy and Biomarkers(40), Renal and related cancers(22), Epigenetics and DNA Methylation(17), Ferroptosis and cancer prognosis(15)

Publications150 total

Muscle Strength Training and Monitoring Device Based on Triboelectric Nanogenerator for Knee Joint Surgery
Micromachines·2025Open Access
Figure S1 from An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas
2025Open Access
Supplementary Tables TS1-23 from An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas
2025Open Access
Figure S4 from An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas
2025Open Access
Figure S8 from An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas
2025Open Access
Figure S6 from An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas
2025Open Access
Figure S3 from An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas
2025Open Access
Figure S5 from An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas
2025Open Access
Figure S2 from An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas
2025Open Access
Figure S7 from An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas
2025Open Access
Table S2 from Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma
2025Open Access
Table S1 from Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma
2025Open Access
Supplementary Figure Annotations from Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma
2025Open Access
Table S3 from Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma
2025Open Access
Supplementary Figures from Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma
2025Open Access
Table S4 from Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma
2025Open Access
457 GABA promotes resistance to immunotherapy of patients with TLS-positive tumours
Regular and Young Investigator Award Abstracts·2025Open Access
Exploring the Potential of Non-Viral Nanocarriers for Improving Blood-Brain Barrier Permeability to Enhance the Treatment of Brain Diseases
International Journal of Nanomedicine·2025· 2 citedOpen Access
Enhanced efficacy of ipilimumab plus nivolumab in angiogenic subtypes of metastatic clear-cell renal cell carcinoma
npj Precision Oncology·2025Open Access
Stratification system with dual human endogenous retroviruses for predicting immunotherapy efficacy in metastatic clear-cell renal cell carcinoma
Journal for ImmunoTherapy of Cancer·2025· 3 citedOpen Access
page 1 of 8Next →

Frequent Co-authors

Catherine Sautès‐Fridman(17), Wolf H. Fridman(15), Yann Vano(10), Stéphane Oudard(10), Florent Petitprez(9), Maxime Meylan(8), Virginie Verkarre(7), Réza Elaidi(7), Tong Wang(7), Aurélien de Reyniès(6), Claude Leclerc(6), Jianjun Huang(6), Yasmine Belkaid(5), Marco Moreira(5), Mostefa Bennamoun(5), Jason A. Hall(4), Antoine Bougoüin(4), Étienne Becht(4), Lubka T. Roumenina(4), Christine Chevreau(4)